Clinical trials explained: Why colour matters…
November 8, 2023 |
Colour can be used to emphasise mood, evoke emotions, and determine first impressions of a brand. Find how to use colour effectively in your next clinical trial campaign.
Just like any product or service, a clinical trial is essentially a brand. It has objectives, a ‘personality’, and a look that helps it to be recognisable and, therefore, trusted. Trial branding also needs to resonate, and empathise, with those people who might take part.
As is the same with all brands, colour plays an important role in creating its identity. Our association with brand colours runs through every aspect of our lives. Think of the red of Coca-Cola, the purple of Cadbury and the blue of the NHS. Barbie pink, anyone?
Colour can be used to emphasise mood, evoke emotions, and determine first impressions of a brand. So, ready to learn a bit more about how colour can help your next clinical trial campaign to stand out and connect with the people who matter?
The psychology of colour
This is where colour psychology (how colours can affect perceptions and behaviour) comes in useful.
For centuries, colour has been used for its therapeutic properties; blues and greens to calm and reassure, yellows and reds to provoke excitement and happiness. But, while there are some common responses to colours, it’s rarely that simple — many things affect how people react. When creating a brand for your trial, patient insights can help to shine a torch on what patients are thinking, their concerns, and what’s important to them. Our experience at Cuttsy+Cuttsy has shown that this can be influenced by many factors, and that paying close attention to them really does pay off.
Using a branding model can help (you can see ours here). Patient insights can be used to shape a trial’s personality and identify the emotions that participants might associate with the study: supported, altruistic, comforted, intrigued, and so on.
What’s the context?
Different colours evoke different emotions and, depending on the context, they can make materials stand out or blend in. Our association with certain colours — and shades — can also influence how appropriate they may be for clinical materials.
There are no hard and fast rules for the use of colour; it’s about what connects with patients. So, it’s crucial to revisit the brand model and assess the impact of colour for your audience.
Colour for everyone
Once an initial palette has been selected for your clinical trial, there are some practical matters to consider. Colour blindness, visual impairments, neurodiversity and even some medications can affect how an individual perceives colour. At Cuttsy+Cuttsy, we carefully consider colour psychology, together with other design elements, when working with our partners to finalise the branding colours for their clinical trials.
Understanding the power of colour and marrying it with the needs and perceptions of potential participants is a key part of clinical trial identity, personality, and gravitas. Is this something you would like to explore for your next clinical trial? If so, and you’d like a colour consultation, let’s talk.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.
Where translation falls short in practice
Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.